Amie Scott Email and Phone Number

Direct design of RWE studies, ensuring alignment of RWD, methods. Execute strategies to deliver scientifically robust evidence. Implement analyses, monitor progress of vendors/internal analytic teams.• Play a key role partnering to transfer data from registries (Corrona, BADBIR, PROSEPCT, PURE, REALIA, SERENA) onto a common platform, enabling execution of company-wide initiatives.• Present available data from RW studies for the “Response to PRAC PSUR Assessment Report” which led to the inclusion of RWE in this Legally Binding Measure (LEG).• Oversee vendor relationships, e.g., Adelphi Real-World/Quantify Research, for non-interventional study (NIS) completion; submitted target publication to drive Cosentyx value demonstration.

Streamlined reporting practices of internal database analyses for all RWE franchise studies.• Led dashboard development, allowing hypothesis testing for a new Cosentyx indication.• Produced template to communicate internal database analysis results; implementation improved transparency and efficiency across Global RWE.

Secured, and executed consulting engagements, presented proposals, and final deliverables to clients. Supervised multidisciplinary team of experts; approved project plans and vendor contracts.• Monitored research integrity to provide clients precise evaluation of new opportunities.• Identified ways in which A.O. Smith could grow global water treatment business, leading to acquisition of Aquasana, Inc. for $87 million.

Integrated rigorous research design into analysis of business processes.• Instituted new research metrics and consulting recommendations, enabling manufacturer (Pentair) to evaluate programs for testing residential water products among U.S. consumers and distributors.

Aligned revenue streams with existing capabilities of the company.• Initiated strategy for New Programs budget refocus on waterborne disease prevention (Legionella)• Launched the Building Water Health program, which enabled expansion of core services (auditing, training, and certification) and addressed water safety for new customers in key markets.

Oversaw psychometric evaluation and linguistic validation of new patient-reported outcome (PRO) measures. Advised on implementation of PRO measures for use in clinical practice and research.• Guided development of user’s guide v1.0 and scoring system for BREAST-Q, BODY-Q, and FACE-Q modules, advancing worldwide use and translation of BREAST-Q into 13 languages, as of 2014.• Enabled inclusion of BREAST-Q in UK audit of 8,000 patients, adoption by American Society of Plastic Surgeons as its outcome measure, and integration into the MSKCC patient portal.

Coordinated data collection and supervised qualitative content analysis for developing new patient-reported outcome measures. Participated in item generation, scale development, and module structure.

Facilitated pilot and field-testing phases of questionnaire development in a cohort of 2000 women. Managed data collection for a multi-center study of Parents of Children with Cancer.

Responsible for HPLC and mass spectrometry quantification techniques, standard operating procedures, maintenance, calibration, and production of therapeutic drug monitoring reports.